 |
 |
马萨诸塞州的剑桥和波士顿德国柏林，1月22,2019 / B金宝搏官网mg3C新闻/ -Crisprperperapeutics.(纳斯达克股票代码:CRSP)是一家生物制药公司，专注于为严重疾病开发变革性基因药物ProBioGen今天，德国领先的服务和技术提供商宣布了一项多年的研究合作，重点是开发新型的体内利用ProBioGen现有的技术和专业知识，为CRISPR/Cas9提供交付模式。
“我们的CRISPR/Cas9平台在一系列毁灭性的、基因定义的疾病上具有变革潜力，”Tony Ho，M.D.，CrispRup疗法副总裁，研发执行副总裁，研发．“为确保我们提供这一潜力，我们继续寻求开拓新技术和能力以支持我们的计划。我们期待着与掌柜团队合作并利用他们的专业知识，以提高我们在体内交付CRISPR / CAS9的研究和开发工作。“
ProBioGen的首席科学官Volker Sandig博士说:“我们很高兴能够在体内交付Crispr / Cas9的新技术联合开发新技术的一个项目中开始。本协议将两家公司的想法，专业知识和经验结合在一起，我们期待通过这一合作加强船队治疗性的高度创新方法。“
没有披露合作的技术和财务细节。合作包括在成功完成研究目标后的CRISPR治疗方法的许可选择。
关于Crisprperperapeutics.
CRISPR Therapeutics是一家领先的基因编辑公司，专注于利用其专有的CRISPR/Cas9平台开发用于严重疾病的变革性基因药物。CRISPR/Cas9是一种革命性的基因编辑技术，可以对基因组DNA进行精确、直接的改变。CRISPR Therapeutics成立了一系列治疗项目，涵盖血红蛋白病、肿瘤、再生医学和罕见疾病等广泛的疾病领域。为了加快和扩大其努力，CRISPR Therapeutics已经与包括拜耳公司、Vertex制药公司和ViaCyte公司在内的领先公司建立了战略合作关系。CRISPR Therapeutics AG总部位于瑞士Zug，其全资子公司CRISPR Therapeutics, Inc.位于马萨诸塞州剑桥市，研发部门位于马萨诸塞州剑桥市，商务办公室位于英国伦敦。
关于ProBioGen
ProBioGen是一家总部位于柏林的专业研发和生产复杂治疗性糖蛋白的公司。结合两种最先进的开发平台，基于ProBioGen的CHO。RiGHT®表达和制造平台，结合智能产品专用技术，生产性能优化的生物制剂。快速和集成的细胞系和工艺开发，全面的分析开发和遵循可靠的GMP生产由一个高度熟练和经验丰富的团队执行。所有的服务和技术都嵌入到一个全面的质量管理体系中，以确保符合国际ISO和GMP标准(EMA/FDA)。ProBioGen公司成立于1994年，是一家位于德国柏林的私营企业。
CRISPR前瞻性陈述
This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) clinical trials (including, without limitation, the timing of filing of clinical trial applications and INDs, any approvals thereof and the timing of commencement of clinical trials), development timelines and discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics and its collaborators; (ii) the number of patients that will be evaluated, the anticipated date by which enrollment will be completed and the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials; (iii) the scope and timing of ongoing and potential future clinical trials; (iv) the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties; (v) the sufficiency of CRISPR Therapeutics’ cash resources; and (vi) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the outcomes for each CRISPR Therapeutics’ planned clinical trials and studies may not be favorable; that one or more of CRISPR Therapeutics’ internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics’ product candidates; uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics’ product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; uncertainties regarding the intellectual property protection for CRISPR Therapeutics’ technology and intellectual property belonging to third parties; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics’ most recent annual report on Form 10-K, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website atwww.sec.gov．现有的和潜在的投资者被警告不要过度依赖这些前瞻性陈述，这些陈述仅在他们作出之日起生效。除法律规定的范围外，CRISPR Therapeutics不承担更新或修订本新闻稿中所载前瞻性陈述的任何义务或承诺。
188bet体育滚球联系人
CRISPR投资者联系:188bet体育滚球
苏珊金
此电子邮件地址正受到垃圾邮件程序的保护。您需要启用JavaScript才能查看它。
CRISPR媒体联系人：188bet体育滚球
詹妮弗Paganelli
WCG代表CRISPR
+1 347 658 8290
此电子邮件地址正受到垃圾邮件程序的保护。您需要启用JavaScript才能查看它。
Probiogen AG联188bet体育滚球系人：
加布里埃尔博士施耐德
首席商务官员
probiogen Ag
Goethestr 54。
13086柏林，德国
+49（0）30 924 006-0
此电子邮件地址正受到垃圾邮件程序的保护。您需要启用JavaScript才能查看它。
由B3C新闻专线出版并分享金宝搏官网mgeveronic®